Patients’ priorities in selecting chronic lymphocytic leukemia treatments-Reference-Cited by-同舟云学术

Patients’ priorities in selecting chronic lymphocytic leukemia treatments

Published:2017-10-31 Issue:24 Volume:1 Page:2176-2185
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Mansfield Carol¹,Masaquel Anthony²,Sutphin Jessie¹,Weiss Elisa³,Gutierrez Meghan⁴,Wilson Jennifer³,Boeri Marco¹,Li Jia²,Reyes Carolina²

Affiliation:

1. RTI Health Solutions, Research Triangle Park, NC;

2. Genentech Inc., South San Francisco, CA;

3. The Leukemia & Lymphoma Society, Rye Brook, NY; and

4. Lymphoma Research Foundation, New York, NY

Abstract

Key Points CLL patients value higher PFS but would accept significant reductions in PFS to avoid serious adverse events. Adding even modest out-of-pocket costs changed treatment choices for hypothetical treatments, suggesting patients are sensitive to cost.

Publisher

American Society of Hematology

Subject

Hematology

Link

http://ashpublications.org/bloodadvances/article-pdf/1/24/2176/879058/advances007294.pdf

Reference27 articles.

1. Leukemia and Lymphoma Society. Facts 2015-2016. https://www.lls.org/sites/default/files/file_assets/Facts_2015_2016_4_16_FINAL.pdf. Accessed 13 January 2017.

2. American Cancer Society. Cancer facts and figures. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2017/cancer-facts-and-figures-2017.pdf. Accessed 26 July 2017.

3. Mir MA . Chronic lymphocytic leukemia (CLL). http://emedicine.medscape.com/article/199313-medication#showall. Accessed 13 January 2016.

4. Food and Drug Administration (FDA). Drugs@FDA: FDA approved drug products. 2017. http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm. Accessed 13 January 2016.

5. Updating the American Society of Clinical Oncology Value Framework: revisions and reflections in response to comments received;Schnipper;J Clin Oncol,2016

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Understanding the experience, treatment preferences and goals of people living with chronic lymphocytic leukemia (CLL) in Australia;BMC Cancer;2024-07-11

2. Elicitation of societal preferences for chronic lymphocytic leukemia’s treatments: a discrete choice experiment;Leukemia & Lymphoma;2024-07-09

3. Patient preferences for chronic lymphocytic leukemia treatments: a discrete-choice experiment;FUTURE ONCOL;2024

4. The value of knowing: preferences for genetic testing to diagnose rare muscle diseases;Orphanet Journal of Rare Diseases;2024-04-22

5. Ibrutinib in CLL: benefit for all?;Blood;2024-04-18